Regulated information

2008 Interim Revenues increase by 5%

Vétoquinol generated revenues of 116.7 million euros in the first half of 2008, a 5% increase over the 111.1 million euros
reported the previous year.

Earnings for 2007 attest to strength of business growth model

The Vétoquinol board of directors, meeting on February 22, 2008, reviewed the group’s business in 2007 and approved the related financial statements. In 2007, Vétoquinol once again achieved significant improvement in its key performance
indicators, ahead of its medium-term targets. According to the most recent statistics published by Vetnosis, this substantial rise in revenue has lifted Vétoquinol to third place
worldwide.

Financial report 2007

Consolidated 2007 figures are even better than the targets in the business plan we presented for the initial public offering (IPO) in November 2006.
<br>
Revenues rose by 10.3% to 233.4 million euros (211.6 million euros in 2006), including 7.6% organic growth.
<br>
The operating profit from continuing operations increased by 13.9%, from 25.6 million euros in 2006 to 29.2 million euros in 2007.
<br>
Finally, net profit increased by 17.8% to 18.6 million euros in 2007 (15.8 million euros in 2006), for a net margin of 8% (7.5% the previous year).

KIBOW BIOTECH INC. et Vétoquinol S.A. étendent leur accord de commercialisation et de licence vétérinaire pour des applications mondiales (french)

Mis en oeuvre des recommandations AFEP/MEDEF du 6 octobre 2008 sur les rémunérations des dirigeants mandataires sociaux des sociétés cotées

Lors de sa réunion du 5 décembre 2008, le Conseil d’administration a pris connaissance des recommandations AFEP-MEDEF du 8 octobre 2008 sur la rémunération des dirigeants sociaux des sociétés cotées.

Pierre Konareff est nommé Directeur Financier et Juridique du Groupe Vétoquinol (french)

Vétoquinol annonce la nomination de Pierre Konareff au poste de Directeur Financier et Juridique du groupe.

Revenue grows by 10.3% in 2007, to €233.4 M

Revenues for the first nine months of 2008

Revenues increased by 3.1% during the first 9 months of 2008 to 171.2 million euros (4.8% on a like-for-like basis).

Satisfactory revenue growth for 1st quarter 2008: +4.6% on a constant basis

Revenue for the first quarter of 2008 reached €54.7 M, an increase of 3.0% over the first quarter of 2007, a high revenue growth period. First quarter 2008 growth was particularly significant for the livestock segment.

VÉTOQUINOL S.A. and JUROX PTY LTD extend their collaboration on ALFAXAN® in Europe